Skip to main content
. 2020 Mar 18;8(1):134. doi: 10.3390/vaccines8010134

Figure 2.

Figure 2

rFSAV stimulates protective immunity in a S. aureus sepsis model. (A,B) Efficacy of rFSAV on the spread of S. aureus. BALB/c mice (n = 10) were immunized with rFSAV and challenged with MRSA252 at 3.0 × 108 CFUs/mouse by tail intravenous injection. The number of viable bacteria in the blood, kidney and spleen of mice (n = 10) at 1 and 3 days post-infection were shown. Data were presented in box and whisker plots, and the medians are shown. Differences were compared to determine their significance using Student’s t-test. (C) BALB/c mice (n = 10) were immunized with rFSAV and challenged with MRSA at 6.0 × 108 CFUs/mouse on 8, 18 and 68 days post the first immunization by tail intravenous injection. (D–G) BALB/c mice (n = 10) were immunized with rFSAV and challenged with JN-75, CQ-19, GZ-02 and KM-22 (3.0 × 108, 5.0 × 108, 7.0 × 108 and 2.0 × 108 CFUs/mouse, respectively) on 18 days. (C–G) The survival rate was monitored for 10 days. The p-values were calculated using the Mantel-Cox log-rank test.